Epoch Investment Partners Inc. Lowers Stake in Charles River Laboratories International, Inc. (NYSE:CRL)

Epoch Investment Partners Inc. reduced its holdings in shares of Charles River Laboratories International, Inc. (NYSE:CRL – Get Rating) by 29.0% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 24,364 shares of the medical research company’s stock after selling 9,956 shares during the period. Epoch Investment Partners Inc.’s holdings in Charles River Laboratories International were worth $9,180,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also modified their holdings of the company. Northwestern Mutual Wealth Management Co. raised its holdings in Charles River Laboratories International by 15.8% in the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 703 shares of the medical research company’s stock worth $265,000 after buying an additional 96 shares during the last quarter. Intercontinental Wealth Advisors LLC raised its holdings in Charles River Laboratories International by 67.8% in the fourth quarter. Intercontinental Wealth Advisors LLC now owns 2,446 shares of the medical research company’s stock worth $922,000 after buying an additional 988 shares during the last quarter. Brinker Capital Investments LLC raised its holdings in Charles River Laboratories International by 20.3% in the fourth quarter. Brinker Capital Investments LLC now owns 6,172 shares of the medical research company’s stock worth $2,325,000 after buying an additional 1,041 shares during the last quarter. Central Bank & Trust Co. purchased a new position in Charles River Laboratories International in the fourth quarter worth about $1,932,000. Finally, Tokio Marine Asset Management Co. Ltd. raised its holdings in Charles River Laboratories International by 12.9% in the fourth quarter. Tokio Marine Asset Management Co. Ltd. now owns 685 shares of the medical research company’s stock worth $258,000 after buying an additional 78 shares during the last quarter. 93.06% of the stock is owned by institutional investors.

Shares of Charles River Laboratories International stock opened at $232.64 on Friday. The firm has a fifty day moving average of $266.50 and a two-hundred day moving average of $315.48. The company has a debt-to-equity ratio of 1.02, a quick ratio of 1.12 and a current ratio of 1.34. The company has a market cap of $11.82 billion, a P/E ratio of 28.34, a PEG ratio of 1.42 and a beta of 1.27. Charles River Laboratories International, Inc. has a one year low of $217.20 and a one year high of $460.21.

Charles River Laboratories International (NYSE:CRL – Get Rating) last issued its quarterly earnings data on Wednesday, May 4th. The medical research company reported $2.75 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.71 by $0.04. Charles River Laboratories International had a return on equity of 21.90% and a net margin of 11.64%. The firm had revenue of $913.93 million during the quarter, compared to the consensus estimate of $908.64 million. During the same period in the previous year, the firm posted $2.53 EPS. The company’s quarterly revenue was up 10.8% compared to the same quarter last year. As a group, equities analysts predict that Charles River Laboratories International, Inc. will post 11.63 earnings per share for the current year.

In related news, Director George Massaro sold 178 shares of the company’s stock in a transaction on Monday, May 9th. The stock was sold at an average price of $230.96, for a total transaction of $41,110.88. Following the completion of the transaction, the director now directly owns 4,677 shares in the company, valued at approximately $1,080,199.92. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, CEO James C. Foster sold 17,436 shares of the company’s stock in a transaction on Tuesday, February 22nd. The stock was sold at an average price of $288.67, for a total value of $5,033,250.12. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 18,010 shares of company stock valued at $5,189,530. Insiders own 1.10% of the company’s stock.

A number of analysts have recently commented on the stock. Deutsche Bank Aktiengesellschaft reduced their price target on shares of Charles River Laboratories International from $409.00 to $350.00 and set a “buy” rating for the company in a research note on Thursday, February 17th. Wells Fargo & Company reduced their price target on shares of Charles River Laboratories International from $390.00 to $325.00 and set an “overweight” rating for the company in a research note on Monday, April 25th. KeyCorp reduced their price target on shares of Charles River Laboratories International from $390.00 to $300.00 in a research note on Thursday, May 5th. Morgan Stanley reduced their price target on shares of Charles River Laboratories International from $465.00 to $430.00 and set an “overweight” rating for the company in a research note on Thursday, February 17th. Finally, UBS Group reduced their price target on shares of Charles River Laboratories International from $465.00 to $420.00 and set a “buy” rating for the company in a research note on Thursday, February 17th. Five investment analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $387.88.

Charles River Laboratories International Profile (Get Rating)

Charles River Laboratories International, Inc, a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).

See Also